Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  NASDAQ OMX COPENHAGEN  >  Novo Nordisk A/S    NOVO B   DK0060534915

NOVO NORDISK A/S

(NOVO B)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Summary
  • The company has strong fundamentals. More than 70% of listed companies have a lower mix of growth, profitability, debt and visibility criteria.
Strengths
  • Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
  • Sales forecast by analysts have been recently revised upwards.
Weaknesses
  • The share is close to its long-term resistance in weekly data. Therefore, the potential should be limited. However, a further bullish movement when crossing this resistance will be a positive signal.
  • Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
  • The company's "enterprise value to sales" ratio is among the highest in the world.
  • The company benefits from high valuations in earnings multiples.
Ratings chart
Sector Pharmaceuticals - NEC
1st jan.Capitalisation (M$)Investor Rating
NOVO NORDISK A/S5.61%141 503
JOHNSON & JOHNSON-8.72%345 705
ROCHE HOLDING AG2.77%277 060
MERCK & CO., INC-16.16%195 141
NOVARTIS-12.10%187 703
PFIZER, INC.-14.14%181 075
BRISTOL-MYERS SQUIBB COMPAN..-13.49%126 110
ELI LILLY AND COMPANY6.26%125 824
AMGEN INC.-14.79%119 572
ASTRAZENECA PLC-8.24%117 896
ABBVIE INC.-17.13%112 508
SANOFI-11.31%110 172
GLAXOSMITHKLINE-16.07%93 854
CHUGAI PHARMACEUTICAL CO., ..0.77%63 605
ALLERGAN PLC-8.09%58 266
JIANGSU HENGRUI MEDICINE CO..0.94%57 229
More Results
Financials (DKK)
Sales 2020 130 B
EBIT 2020 55 091 M
Net income 2020 42 324 M
Finance 2020 13 373 M
Yield 2020 2,22%
P/E ratio 2020 22,6x
P/E ratio 2021 19,9x
EV / Sales2020 7,28x
EV / Sales2021 6,81x
Capitalization 958 B
Upcoming event on NOVO NORDISK A/S
Surperformance© ratings
  Help  
Fundamental ratings
Overall rating
Trading Rating
Investor Rating
Growth (Revenue)
Valuation
Finances
Profitability
Earnings quality
Business Predictability
P/E ratio
Potential
Yield
Consensus
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision
Technical ratings
Short Term Timing
Middle Term Timing
Long Term Timing
RSI
Bollinger Spread
Unusual Volumes